Complex drug interactions of HIV protease inhibitors 1: Inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir

Drug Metabolism and Disposition

Volumn 39, Issue 6, 2011, Pages 1070-1078

  Kirby, Brian J ^a   Collier, Ann C ^a   Kharasch, Evan D ^b   Whittington, Dale ^a   Thummel, Kenneth E ^a   Unadkat, Jashvant D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; MIDAZOLAM; NELFINAVIR; RIFAMPICIN; RITONAVIR;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; INTESTINE; LIVER CELL; LIVER MICROSOME; MALE; MORNING DOSAGE; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TISSUE SPECIFICITY; TREATMENT DURATION; VOLUNTEER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CELLS, CULTURED; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME ACTIVATION; ENZYME INDUCTION; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; INJECTIONS, INTRAVENOUS; INTESTINES; LIVER; MALE; MIDAZOLAM; MIDDLE AGED; NELFINAVIR; RIFAMPIN; RITONAVIR; SUBSTRATE SPECIFICITY; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 79956136652     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.037523     Document Type: Article

References (28)

1. Almond LM, Yang J, Jamei M, Tucker GT, and Rostami-Hodjegan A (2009) Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. Curr Drug Metab 10:420-432.
2. Bardsley-Elliot A and Plosker GL (2000) Nelfinavir: an update on its use in HIV infection. Drugs 59:581-620. (Pubitemid 30213865)
3. Culm-Merdek KE, von Moltke LL, Gan L, Horan KA, Reynolds R, Harmatz JS, Court MH, and Greenblatt DJ (2006) Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther 79:243-254.
4. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, and Unadkat JD (2007) Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 35:1853-1859. (Pubitemid 47481578)
5. Ernest CS 2nd, Hall SD, and Jones DR (2005) Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312:583-591. (Pubitemid 40189555)
6. Fahmi OA, Boldt S, Kish M, Obach RS, and Tremaine LM (2008a) Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes. Drug Metab Dispos 36:1971-1974.
7. Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A, Hyland R, et al. (2009) Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos 37:1658-1666.
8. Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, and Nettleton D (2008b) A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 36:1698-1708.
9. Greenblatt DJ, Peters DE, Oleson LE, Harmatz JS, MacNab MW, Berkowitz N, Zinny MA, and Court MH (2009) Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. Br J Clin Pharmacol 68:920-927.
10. Greenblatt DJ, von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C, Kelley CJ, LeDuc BW, and Zinny MA (2003) Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther 74:121-129. (Pubitemid 36951809)
11. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL, and Shader RI (2000a) Alprazolam-ritonavir interaction: implications for product labeling. Clin Pharmacol Ther 67:335-341. (Pubitemid 30246808)
12. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL, and Shader RI (2000b) Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 24:129-136. (Pubitemid 30640958)
13. Gupta A, Mugundu GM, Desai PB, Thummel KE, and Unadkat JD (2008) Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors. Drug Metab Dispos 36:1172-1180. (Pubitemid 351717476)
14. Hsu A, Granneman GR, Witt G, Locke C, Denissen J, Molla A, Valdes J, Smith J, Erdman K, Lyons N, et al. (1997) Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 41:898-905. (Pubitemid 27194157)
15. Hughes CA, Freitas A, and Miedzinski LJ (2007) Interaction between lopinavir/ritonavir and warfarin. CMAJ 177:357-359. (Pubitemid 47339532)
16. Kharasch ED, Walker A, Hoffer C, and Sheffels P (2004) Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther 76:452-466. (Pubitemid 39469869)
17. Kirby B, Kharasch ED, Thummel KT, Narang VS, Hoffer CJ, and Unadkat JD (2006) Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities. J Clin Pharmacol 46:1313-1319. (Pubitemid 44564360)
18. Kirby BJ and Unadkat JD (2010) Impact of ignoring extraction ratio when predicting drug-drug interactions, fraction metabolized, and intestinal first-pass contribution. Drug Metab Dispos 38:1926-1933.
19. Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E, Orza D, Marinina J, and Gerber N (1998) Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 26:552-561. (Pubitemid 28498361)
20. Kumar GN, Rodrigues AD, Buko AM, and Denissen JF (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277:423-431. (Pubitemid 27169089)
21. Lillibridge JH, Liang BH, Kerr BM, Webber S, Quart B, Shetty BV, and Lee CA (1998) Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 26:609-616. (Pubitemid 28345843)
22. Obach RS, Walsky RL, and Venkatakrishnan K (2007) Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246-255. (Pubitemid 46148737)
23. Ripp SL, Mills JB, Fahmi OA, Trevena KA, Liras JL, Maurer TS, and de Morais SM (2006) Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos 34:1742-1748. (Pubitemid 44427477)
24. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491-502. (Pubitemid 26193889)
25. Tran TH, Von Moltke LL, Venkatakrishnan K, Granda BW, Gibbs MA, Obach RS, Harmatz JS, and Greenblatt DJ (2002) Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab Dispos 30:1441-1445. (Pubitemid 35397052)
26. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, and Hall SD (2001) The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 70:317-326. (Pubitemid 33022472)
27. Zeldin RK and Petruschke RA (2004) Pharmacological and therapeutic properties of ritonavirboosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 53:4-9. (Pubitemid 38072176)
28. Zhao P (2008) The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo. Expert Opin Drug Metab Toxicol 4:151-164.